Indian stocks: Visit www.stage2stocks.com →

Denali Therapeutics Inc.

Stage 3 · Topping · week 6

As of Oct 22, 2026, Denali Therapeutics is in Stage 3, the topping phase, now in week 6 (since Sep 16, 2026). It closed at $18.66, 31.4% below its 52-week high and below its 200-day average, which is rising.

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. More about the company

$18.66
-0.11% today
$3.0B · Mid cap
Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is DNLI early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 19w
S2 22w
S4 20w
S2 22w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S3 1w → S4 19w → S1 3w → S4 9w → S1 5w → S4 6w → S1 2w → S2 22w → S3 8w → S4 20w → S1 5w → S4 4w → S1 5w → S4 3w → S1 5w → S2 22w → S3 8w → S2 13w → S3 5w current
Total tracked: 165 weeks across 19 stage runs.

DNLI among Biotechnology154th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…154DNLIStage 3 · wk 662−8.8%
vs 52W High
-31.4%
$14.41 lo$27.21 hi
31.4% below 52W high, weakening from peak
The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.
Stage Maturity
Week 6
1w13w26w
Week 6, distribution
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
-12.0%
200 DMA: $21.19 · rising
Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.
Rel Volume
0.50x
vs 50-day avg
Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-8.8%
3M
-19.3%
6M
-4.1%
YTD
+14.7%
1Y
+10.0%
Scan Membership
Breakout Watch
Latest: 2024-07-02
9 appearances in last 60 days. First seen: 2018-12-31.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S3
Wk 6 · Vol 0.50x
2026-10-21S3
Wk 6 · Vol 0.72x
2026-10-20S3
Wk 5 · Vol 1.13x
2026-10-19S3
Wk 5 · Vol 1.69x
2026-10-16S3
Wk 5 · Vol 1.43x
2026-10-15S3
Wk 5 · Vol 0.98x
2026-10-14S3
Wk 5 · Vol 1.73x
2026-10-13S3
Wk 4 · Vol 1.25x
2026-10-12S3
Wk 4 · Vol 0.79x
2026-10-09S3
Wk 4 · Vol 0.86x
2026-10-08S3
Wk 4 · Vol 1.55x
2026-10-07S3
Wk 4 · Vol 0.85x
Moving averages & range
50 DMA
$21.33
200 DMA
$21.19
52W High
$27.21
52W Low
$14.41
5D Low
$17.61
Resistance levels (recent highs)
20d High
$20.98
60d High
$25.69
120d High
$27.21
250d High
$27.21
Next resistance
+12.4%
to 20d High
ROE
-54.9%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 3.6

Denali Therapeutics: quick answers

What stage is Denali Therapeutics in?

As of Oct 22, 2026, Denali Therapeutics (DNLI) is in Stage 3, the topping phase. It entered Stage 3 on Sep 16, 2026 and is in week 6. What the four stages mean

Is Denali Therapeutics in an uptrend?

Its uptrend has stalled. Denali Therapeutics is in Stage 3, the topping phase that follows an advance. It trades 12.0% below its 200-day average, which is rising.

How far is Denali Therapeutics from its 52-week high?

Denali Therapeutics closed at $18.66 on Oct 22, 2026, 31.4% below its 52-week high of $27.21. Its 52-week low is $14.41.

How has Denali Therapeutics performed over the past year?

As of Oct 22, 2026, Denali Therapeutics is up 10.0% over the past year and up 14.7% so far in 2026.

Which sector and industry is Denali Therapeutics in?

Denali Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.